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Matti S. Aapro A]ways more "setrons": 
how many do we need? 
The possible abuse of "setrons" in 
radiation oncology [1] has been re- 
cently discussed, not to mention 
the confusing issues about the use 
of these excellent agents in the 
prevention of delayed emesis and 
in the area of post-anesthesia n u- 
sea and vomiting. This journal is- 
sue contains several important con- 
tributions to the area of cytotoxic 
drug induced nausea and vomiting. 
It actually opens with a glimpse at 
the future by S. M. Grunberg, 
which addresses everal issues, 
both methodological nd new 
agents, such as the NK-1 receptor 
antagonists [3]. Several such new 
agents are presently under devel- 
opment, and in view of the promis- 
ing results of the initial clinical 
studies he cites, äcute and delayed 
emesis might be better controlled 
than with present-day combina- 
tions. If such agents could decrease 
the use of steroids in potentially 
curative settings, they could be of 
benefit to the patient, as reasona- 
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ble doubt about the chronic use of 
of prednisone (admittedly a differ- 
ent approach from short-term an- 
tiemetic usage) has recently been 
expressed in the setting of adjuvant 
therapy for breast cancer [6]. Oth- 
er mechanisms of antiemetic action 
could also be developed, using our 
knowledge of peptide YY, a good 
candidate as a mediator of emesis 
[9]. One might also want to look at 
mixed 5-HT3 receptor antagonists/ 
5-HT4 receptor agonists, such as R- 
zacopride, which is under develop- 
ment at present, and not forget the 
potential of drugs like metopima- 
zine, as discussed by Herrstedt et 
al. [4]. It is true, as D. Warr says in 
his contribution in this issue of 
Supportive Care in Cancer, that a 
combination of a 5-HT3 receptor 
antagonist and a corticosteroid 
should be considered a standard in 
the prevention of chemotherapy-in- 
duced acute nausea and vomiting, 
while the role of the "setrons" in 
delayed emesis seems modest [10]. 
As resources allocated for health- 
related issues are becoming more 
and more scarce, it is mandatory to 
discuss the cost-benefit ratio of the 
use of many drugs, and certainly 
one can advocate the use of mod- 
ern combinations in preventing 
emesis when a high proportion of 
patients (what is "high"?) can be 
expected to vomit if left untreated. 
Guidelines are needed in the same 
spirit of those that have already 
been developed for the use of he- 
mopoietic growth factors; the Mul- 
tidisciplinary Association for Sup- 
portive Care in Cancer (MASCC) 
will soon issue internationally valid 
recommendations, a  it seems diffi- 
cult to follow the already existing 
Canadian ones [7] or the soon to 
be published American ones. How- 
ever, one should not forget that 
the world also uses curative, but 
highly emetogenic chemotherapies 
in countries with extremely limited 
resources. What can be done 
there? In my eyes, companies 
should offer the "setrons" at cost 
in these settings, and in these 
countries one should not forget 
that metoclopramide and corticos- 
teroids are an acceptable and effec- 
tive combination, when properly 
used, and could still be offered as a 
first-line preventative combination 
for most cancer patients. But 
maybe the cost of "setrons" will be 
pushed even lower, as the competi- 
tion in the market becomes even 
fiercer. In most areas of the world 
we already have granisetron, on- 
dansetron and tropisetron, with 
variable commercial names. (When 
will we have a single commercial 
name all over the world? When 
will authorities accept hat many 
travel today?) These agents are 
uniformly efficacious for the pre- 
vention of acute chemotherapy-in- 
duced nausea and vomiting. There 
are no data from properly con- 
trolled randomized studies to sug- 
gest a major clinically significant 
difference in efficacy between 
these agents, at least when they are 
used at an adequate dose, as dis- 
cussed by Perez et al. for granise- 
tron [8] and by Warr for ondanse- 
tron [10]. So now we have in this 
issue a paper about a new "se- 
tron," which is being introduced in 
many countries: dolasetron. The 
development of this agent from 
phase I [5] until now makes orte 
wonder, as with ramosetron, azase- 
tron and others, if we really had to 
devolop another "setron." From 
the data reported in the paper first 
authored by the late B. Chevallier, 
it is evident that dolasetron is an 
efficacious and well-tolerated agent 
[2]. There are many other papers 
about the phase I I I  studies with 
dolasetron, and a couple are al- 
luded to in D. Warr's review. What 
do these papers tell us about this 
agent? Nothing of substance, noth- 
ing that might make one decide to 
change his or her prescribing ha- 
bits. Where is the advantage of this 
agent? We cannot find evidence of 
an advantage in efficacy, in sched- 
ule, in formulation, or in side ef- 
fects. The preclinical studies also 
did not indicate a major advantage 
for this agent compared to the oth- 
er available antiemetics. The realo 
ity is that the development of this 
cousin of MDL 72'222, the first 5- 
HT3 receptor antagonist to be 
tested as an antiemetic, has been 
slower than that of its analogues. 
Do we then need new "setrons"? 
Yes, because when highly reputa- 
ble companies bring new agents of 
the same class into the market, it 
tends to stabilize and usually de- 
crease the prices of the com- 
pounds. This is at least what hap- 
pened in many of those markets 
where granisetron or tropisetron 
were introduced to compete with 
one or two other "setrons." We 
can thus hope that at least this as- 
pect will be favorable for the pa- 
tient and strongly recommend that 
"setrons" that are still being devel- 
oped should be brought to the 
phase I I I  level only if they have, 
on top of their 5-HT3 receptor an- 
tagonist activity, at least some oth- 
er advantage, i.e., if they actually 
inhibit other mechanisms. Let us 
remember how long one thought 
that high-dose metoclopramide was 
a dopamine receptor antagonist 
until its 5-HT3 receptor antagonist 
activity was actually understood. 
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